| Proteomic identification of a marker signature for MAPK i resistance in melanoma V Paulitschke, O Eichhoff, C Gerner, P Paulitschke, A Bileck, T Mohr, ... The EMBO journal 38 (15), e95874, 2019 | 31 | 2019 |
| Octenidine-based hydrogel shows anti-inflammatory and protease-inhibitory capacities in wounded human skin S Seiser, L Janker, N Zila, M Mildner, A Rakita, J Matiasek, A Bileck, ... Scientific Reports 11 (1), 32, 2021 | 23 | 2021 |
| Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases N Zila, A Bileck, B Muqaku, L Janker, OM Eichhoff, PF Cheng, R Dummer, ... Clinical proteomics 15, 1-22, 2018 | 18 | 2018 |
| ROS induction targets persister cancer cells with low metabolic activity in NRAS-mutated melanoma OM Eichhoff, CI Stoffel, J Käsler, L Briker, P Turko, G Karsai, N Zila, ... Cancer Research 83 (7), 1128-1146, 2023 | 10 | 2023 |
| Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial A Redl, K Doberer, L Unterluggauer, L Kleissl, C Krall, C Mayerhofer, ... The Lancet Rheumatology 6 (2), e81-e91, 2024 | 6 | 2024 |
| Novel immune checkpoints beyond PD-1 in advanced melanoma N Zila, C Hoeller, V Paulitschke memo-Magazine of European Medical Oncology 14 (2), 135-142, 2021 | 5 | 2021 |
| Proteomic profiling of advanced melanoma patients to predict therapeutic response to anti-PD-1 therapy N Zila, OM Eichhoff, I Steiner, T Mohr, A Bileck, PF Cheng, A Leitner, ... Clinical Cancer Research 30 (1), 159-175, 2024 | 3 | 2024 |
| DNA methylation signatures correlate with response to immune checkpoint inhibitors in metastatic melanoma JM Ressler, E Tomasich, T Hatziioannou, H Ringl, G Heller, R Silmbrod, ... Targeted Oncology 19 (2), 263-275, 2024 | 2 | 2024 |
| Myofibroblast stroma differentiation in infiltrative basal cell carcinoma is accompanied by regulatory T‐cells JM Ressler, N Zila, A Korosec, J Yu, R Silmbrod, V Bachmayr, J Tittes, ... Journal of Cutaneous Pathology 50 (6), 544-551, 2023 | 2 | 2023 |
| 794P Efficacy and tolerability of neoadjuvant treatment with T-VEC in difficult to resect primary basal cell carcinoma: A phase II clinical trial (NeoBCC) JM Ressler, A Kusienicka, R Silmbrod, T Silly, V Bachmayr, M Plaschka, ... Annals of Oncology 33, S907, 2022 | 2 | 2022 |
| JAK-STAT signaling maintains homeostasis in T cells and macrophages N Fortelny, M Farlik, V Fife, AD Gorki, C Lassnig, B Maurer, K Meissl, ... Nature Immunology, 1-13, 2024 | 1 | 2024 |
| Stiffness-dependent LOX regulation via HIF-1 drives extracellular matrix modifications in psoriasis P Balsini, P Weinzettl, D Samardzic, N Zila, M Buchberger, P Tschandl, ... bioRxiv, 2024.05. 14.594058, 2024 | 1 | 2024 |
| Correlation of DNA methylation signatures with response to immune checkpoint inhibitors in metastatic melanoma. JM Ressler, E Tomasich, T Hatziioannou, H Ringl, G Heller, R Silmbrod, ... Journal of Clinical Oncology 41 (16_suppl), 9561-9561, 2023 | 1 | 2023 |
| Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function S Bromberger, Y Zadorozhna, JM Ressler, S Holzner, A Nawrocki, N Zila, ... Life Science Alliance 7 (8), 2024 | | 2024 |
| 124 Lysyl oxidase regulates extracellular matrix modifications in psoriasis P Balsini, D Samardzic, P Weinzettl, M Buchberger, N Zila, D Symmank, ... Journal of Investigative Dermatology 143 (11), S353, 2023 | | 2023 |
| 121 AB cell-rich tumor microenvironment delineates cutaneous T cell lymphoma from benign inflammatory skin diseases J Strobl, R Li, EFM Poyner, L Gardner, B Olabi, E Stephenson, R Botting, ... Journal of Investigative Dermatology 143 (11), S353, 2023 | | 2023 |
| Cutaneous T cell lymphoma atlas reveals malignant Th2 cells supported by a B cell-rich microenvironment R Li, J Strobl, EFM Poyner, F Torabi, P Mazin, NJ Chipampe, ... bioRxiv, 2023.11. 06.565474, 2023 | | 2023 |
| Off-targets of BRAF inhibitors disrupt endothelial signaling and differentially affect vascular barrier function S Bromberger, Y Zadorozhna, JM Ressler, S Holzner, A Nawrocki, N Zila, ... bioRxiv, 2023.08. 24.554606, 2023 | | 2023 |
| ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanoma OM Eichhoff, CI Stoffel, J Käsler, L Briker, P Turko, G Karsai, N Zila, ... bioRxiv, 2022.10. 19.512839, 2022 | | 2022 |
| Proteomic profiling to predict therapeutic response to anti-PD-1 therapy in advanced melanoma N Zila, M Levesque, V Paulitschke JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT 20, 37-37, 2022 | | 2022 |
